Insights

Rare diseases affect an estimated 36 million people across Europe, yet access to life-changing treatments remains one of healthcare's greatest challenges. While advances in genomics, precision medicine and orphan drug development have accelerated innovation, scientific breakthroughs alone are no longer enough to ensure patient access. Today, success in Europe's rare disease landscape is increasingly determined by the ability to navigate complex health technology assessments (

We are delighted to boost our range in placing senior finance leaders. Get to know the newest member of our team!

Joe Knight, who leads our Commercial Life Sciences practice, recounts the presentations and networking event at ZS Associates’ Boston office

The US market has long been the ‘Holy Grail’ for European HealthTech companies. What should they know before taking the plunge? Cristian...

It was great to chat to PursueCare founder and CEO Nick Mercadante for this episode of the Venari Podcast’s HealthTech CEO series! ...

Matthew Palmer spoke to Tiffany for the Venari Podcast It’s fair to say that Tiffany Olson has always kept herself busy. ‘When other...

It’s a tricky topic in the radiopharmaceutical space at present – but Matthew Palmer got insights on the market for young talent from Ken...

In this episode of The Venari Podcast, Michael Paul discusses MARAbio 's mission to mitigate the severe effects of autism. Leveraging a...

As part of our HealthTech CEO series, I really enjoyed chatting with Jens Noertershaeuser , CEO and co-founder of Kranus Health . We...